General company information

Biofrontera aims at attending and treating the skin, recognizing the aesthetic needs of a person's visual reflection.

Company

Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen, Germany,
Tel.: +49 (0)214 87632-0, www.biofrontera.com

Strategy

Biofrontera develops a product portfolio for dermocosmetical products and drugs for dermatological and inflammatory diseases. The company's goal is to establish its own dermatology marketing and sales force in selected European countries, out-licensing the distribution of products in other countries and in indications outside dermatology.

Business

Biofrontera developed two products all the way to market, the prescription medicine Ameluz, which is approved in the entire EU, Norway, Island and Liechtenstein, and the dermo-cosmetic product Belixos. Both Ameluz and Belixos are distributed by Biofrontera Pharma GmbH in Germany and, in the future, some other European countries. For several other countries, Biofrontera forms partnerships with other companies. For Denmark, Sweden and Norway such a partnership deal for the marketing of Ameluz was signed with Desitin Arzneimittel GmbH, Hamburg. Belixos is distributed throughout the Arabic countries (MENA region) by Itrom Trading Drug Store, Dubai.

Company structure

Biofrontera AG is a holding company with two wholly-owned subsidiaries, Biofrontera Bioscience GmbH and Biofrontera Pharma GmbH.

Products

Ameluz	EU-approval to treat actinic keratoses since December 2011.
Belixos	Dermo cosmetic product to care for itchy and inflamed skin marketed since October 2009.

Clinical Pipeline

BF-200ALA	Pilot trials for condyloma and basal cell carcinoma (BCC) successful.
BF-derm1	Successful completion of clinical Phase IIa for antihistamine-refractory urticaria
BF-1	Phase I in clinical development for migraine prophylaxis

Patents

Biofrontera's product portolio is protected by a series of patent families.

Management

Prof. Hermann Lübbert, PhD, CEO
Werner Pehlemann, CFO

Team

With just 30 highly skilled and trained employees, Biofrontera functions as a lean and efficient organization.

Supervisory Board

Jürgen Baumann (chairman), Andreas Fritsch, Ulrich Granzer, PhD, Ulrike Kluge, Alfred Neimke, Prof. Bernd Wetzel, PhD (vice chairman)

Finance

Since 1997 Biofrontera has raised EUR 27.4 mln from investors and EUR 8 mln in grants from federal and state governments and the European Union.
In August 2005 Biofrontera listed a EUR 20 mln convertible bond at the Frankfurt stock exchange.
In October 2006 Biofrontera successfully closed a private placement of 443,514 new shares at a price of EUR 15 per share, generating additional cash of EUR 6.65 mln. All new investors were granted the option to sign up for additional shares at a fixed price of EUR 15. Through the placement of the option shares in 2007 Biofrontera has obtained additional funding of EUR 3.33 mln..
On October 30th 2006 Biofrontera listed its shares in the regulated market (geregelter Markt) of the Düsseldorf stock exchange. The shares are registered under the symbol B8F and the ISIN number DE0006046113.
Since August 2008 until February 2012 Biofrontera had 8 small capital increases, providing the company with a total of 13.2 mln Euro.
Restructuring Biofrontera’s convertible bond reduced the outstanding bond to about 4 mln Euro. Most of the partial debentures eliminated in this process were replaced by two option bonds. The first with 9.1 mln Euro outstanding will be due in Dec. 2016, the other with 4.9 mln Euro outstanding will be due in December 2017.

Goals

Increasing the European sales of Ameluz and Belixos.
Approval of Ameluz in the USA.